ST6GAL1 and lymphoma: In our previous research invasion to galectin‐1 is inhibited by neuraminidase treatment in lymphoma cells.24 Therefore, neuraminidase treatment or knockdown of ST6Gal1, which enhance cell adhesion to the extracellular matrix, may be candidates as tumor therapies by inhibiting lymphoma cell invasion and metastasis.